07 Feb 24 Boosting the success potential of promising Biotech Startups: the o2h kickstarter competition
11 Jan 24 “Empowering Targeted Protein Degradation with Protac Services: Unleashing the Power of E3 Li
23 Oct 23 How o2h Kickstarter Is Empowering Early Stage Biotech Startups: Addressing Key Challenges Head-On
08 Sep 23 o2h discovery launches ‘o2h kickstarter competition 5.0’ to support American early stage biote
07 Aug 23 Protai, a proteomics and AI-powered drug discovery startup wins the o2h kickstarter competition 3.
14 Jul 23 o2h discovery launches the o2h kickstarter competition 4.0 to support Italian early stage biotechs
28 Jun 23 Lipid Nanoparticles: o2h discovery’s expertise in synthesizing phospholipid molecules to sup
27 May 23 Targeted Protein Degradation/PROTAC Services: Revolutionizing the drug discovery approach with PRO
04 May 23 Psylo, a biotech company developing next-gen drugs for psychiatric disorders wins o2h kickstarter
11 Apr 23 We are delighted to launch the first ever Cambridge Wide Open Day to drive inclusive collaboration
13 Mar 23 Biiah, a tech startup committed to improving people’s health through singing, wins the o2h t
13 Mar 23 RouteZero, a greentech startup committed to decarbonising business travel wins the o2h tech kickst
18 Jan 23 o2h discovery launches the o2h kickstarter competition 2.0 to support Australian early stage biote
02 Nov 22 Azadyne, a biotech startup targeting autoimmune disease wins o2h discovery kickstarter competition
03 Oct 22 Kuano Limited, a quantum simulation led biotech company wins o2h discovery kick-starter competitio
25 Aug 22 o2h discovery is exhibiting at the XXVII EFMC ISMC International Symposium on Medicinal Chemistry
21 Jul 22 o2h discovery is sponsoring and exhibiting at the 3rd Molecules Medicinal Chemistry Symposium R
04 May 22 Stingray Bio and o2h discovery initiate a collaboration to develop the next-generation of oncology
03 May 22 o2h group acquires 40,000 sq ft Hauxton Meadows site in Cambridge, UK with plans to develop state-
21 Apr 22 Claudio Dagostin will be representing o2h discovery at the 33rd Medicinal Chemistry Meeting
12 Apr 22 Prashant Shah, CEO of o2h co work labs and Co-Founder of o2h group shortlisted in the Cambridge In
23 Mar 22 o2h discovery is exhibiting at the 8th RSC-BMCS Fragment-based Drug Discovery Meeting – 2022
13 Aug 21 o2h Ventures backed In4Derm enters into an exclusive license agreement with VYNE Therapeutics
05 Aug 21 o2h Ventures ‘Knowledge Intensive Human Health EIS Fund’ invests into BiVictriX Therapeutics
05 Jul 21 Neophore closed £15.2m series B round successfully and expands its drug discovery collaboration w
11 May 21 o2h Ventures backed In4Derm Announces a Strategic Partnership with a Nasdaq listed biotech with a
16 Apr 21 Sunil Shah, CEO of o2h ventures, wins the Cambridge Independent Science and Technology Awards as C
12 Nov 20 o2h ventures launches the first HMRC approved knowledge intensive EIS fund focused on UK biotech t
23 Sep 20 o2h discovery is exhibiting at the 3rd RSC-BMCS / RSC-CICAG Artificial Intelligence in Chemistry s
13 Nov 19 Nilesh Dagia, COO, o2h discovery, wins the International Institute for Sustainable Labs (I2SL) Go
11 Sep 19 Cedilla Therapeutics and o2h discovery are pleased to announce multi FTE expansion to their synthe
12 Aug 19 Chemistry Process Optimization – an inevitable parameter for the developmental phase of the drug
10 Jun 19 Privitar Raises $40 Million Series B Funding Round Led by Accel to Facilitate the Safe and Ethical
18 Oct 18 Arecor secures £6M investment for the clinical development of its diabetes speciality pharma port
22 Jun 18 Press Release – PhoreMost and o2h discovery collaborate to progress first-in-class drug disc
09 May 18 Press release – o2h group acquires the 2.76 acre heritage Hauxton Mill site, Cambridge, UK w
18 Apr 18 Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against
15 Mar 18 We are celebrating o2h Collaborative Innovation Conference, Ahmedabad 2018 at 15th March 2018
13 May 17 o2h group update: Exonate receives Wellcome Trust funding to develop eye drop treatment for wet ag
02 Nov 16 o2h discovery is pleased to announce a 10 FTE Synthetic Chemistry collaboration with Heptares
16 Oct 16 Orfan Biotech, a company dedicated to developing small molecules for the treatment of Primary Hype
16 Oct 16 o2h discovery are working with new Boston based start-up Arrakis, supporting discovery efforts and
26 Apr 15 Investment in the seed round of Phoremost who have developed a next-generation phenotypic screenin